Protalix BioTherapeutics (NYSE:PLX – Get Free Report) and Inhibikase Therapeutics (NYSE:IKT – Get Free Report) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, dividends, profitability, earnings and risk.
Analyst Ratings
This is a breakdown of current recommendations and price targets for Protalix BioTherapeutics and Inhibikase Therapeutics, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Protalix BioTherapeutics | 0 | 0 | 1 | 0 | 3.00 |
| Inhibikase Therapeutics | 0 | 1 | 1 | 0 | 2.50 |
Protalix BioTherapeutics currently has a consensus target price of $15.00, indicating a potential upside of 913.51%. Inhibikase Therapeutics has a consensus target price of $6.50, indicating a potential upside of 233.33%. Given Protalix BioTherapeutics’ stronger consensus rating and higher possible upside, equities analysts plainly believe Protalix BioTherapeutics is more favorable than Inhibikase Therapeutics.
Risk & Volatility
Profitability
This table compares Protalix BioTherapeutics and Inhibikase Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Protalix BioTherapeutics | -21.03% | -30.89% | -11.74% |
| Inhibikase Therapeutics | N/A | -350.63% | -201.82% |
Earnings and Valuation
This table compares Protalix BioTherapeutics and Inhibikase Therapeutics”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Protalix BioTherapeutics | $59.76 million | 1.97 | $8.31 million | $0.04 | 37.00 |
| Inhibikase Therapeutics | $260,000.00 | 557.57 | -$19.03 million | ($2.67) | -0.73 |
Protalix BioTherapeutics has higher revenue and earnings than Inhibikase Therapeutics. Inhibikase Therapeutics is trading at a lower price-to-earnings ratio than Protalix BioTherapeutics, indicating that it is currently the more affordable of the two stocks.
Insider & Institutional Ownership
16.5% of Protalix BioTherapeutics shares are owned by institutional investors. Comparatively, 3.8% of Inhibikase Therapeutics shares are owned by institutional investors. 6.5% of Protalix BioTherapeutics shares are owned by insiders. Comparatively, 7.3% of Inhibikase Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Summary
Protalix BioTherapeutics beats Inhibikase Therapeutics on 8 of the 13 factors compared between the two stocks.
About Protalix BioTherapeutics
Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell-expressed recombinant PEGylated Uricase which is in Phase I trial for the treatment of gout; and PRX-119, a plant cell-expressed PEGylated recombinant human DNase I product candidate that is in preclinical phase for the treatment of NETs-related diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. The company was incorporated in 1993 and is headquartered in Karmiel, Israel. Protalix BioTherapeutics, Inc. is a subsidiary of Protalix Ltd.
About Inhibikase Therapeutics
Inhibikase Therapeutics, Inc., a clinical-stage pharmaceutical company, develops therapeutics for Parkinson’s disease and related disorders. Its lead product candidate is IkT-148009, a non-receptor Abelson tyrosine kinase inhibitor, which is in Phase 2a clinical trials to the treatment of Parkinson’s disease and gastrointestinal tract. The company is also developing IkT-001Pro, a prodrug of the anticancer agent imatinib mesylate to treat stable phase chronic myelogenous leukemia. Inhibikase Therapeutics, Inc. has research and development collaborations with Johns Hopkins University, Arizona State University, and Michigan State University; and a collaborative research and development agreement with Sphaera Pharma Pte. Ltd. The company was founded in 2008 and is headquartered in Atlanta, Georgia.
Receive News & Ratings for Protalix BioTherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Protalix BioTherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
